Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes
Part of paid clinical trials in Charlottesville, Virginia.
- Sponsor
- University of Virginia
- Study ID
- NCT04443153
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Personalized Feedback — DEVICEProvides tailored information to the user about what glycemic risk they may be facing as well as how glycemic control and system use looked in the past week. Treatment decision and therapy changes are entirely left to the decision of the user.
- Decision Support System — DEVICECGM-based system that includes Personalized Feedback (PF) and further assists with treatment recommendations for common metabolic challenges
- Sensor Augmented Mode — DEVICEA mode in Diabetes Assistant (DiAs) that combines Diabetes Assistant, Insulin pump or Multiple Daily Injections, CGM, ketone meters, and glycemic treatment guidelines together to manage diabetes.
Study Details
This study is evaluate the superior efficacy of a Continuous Glucose Monitor (CGM)-based advisory system in Type 1 Diabetes Mellitus (T1DM), as compared to Sensor Augmented Mode (SAM) therapy, and with characterizing the impact of psycho-behavioral factors on system performance, which will enable system individualization and lead to automated adaptation of advice delivery to optimize glycemic control and reduce the system's psychological impact.
Key Dates
- Start date
- Sep 4, 2020
- Status verified
- Oct 2025
- Primary completion
- Sep 19, 2024
- Completion
- Sep 19, 2024
Study Design
- Enrollment
- 88 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: De-escalationSubjects randomized to this arm will proceed from DSS to PF to SAM
- Experimental: EscalationSubjects randomized to this arm will proceed from SAM to PF to DSS
Primary Outcome Measure
Glycemic Outcomes [ Time Frame: Assessed over the last 4 weeks (Weeks 4 - 8), for each intervention ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Virginia Center for Diabetes Technology | Charlottesville | Virginia | 22903 | - |
Find similar trials in Charlottesville, VA
By condition
By specialty
Related Studies
- A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 DiabetesPHASE3 · Recruiting · Vertex Pharmaceuticals Incorporated · Duarte, California
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and AdultsPHASE3 · Recruiting · Eli Lilly and Company · Tallahassee, Florida
- A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)PHASE3 · Recruiting · Eli Lilly and Company · Aurora, Colorado
- TrialNet Pathway to Prevention of T1DRecruiting · University of South Florida · Orange, California